Latest news in cancer
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory...
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell...
Clinical trial recruitment for BALL CAR T-Cell therapy
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D)...
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
Oricell is developing a number of CAR-T therapies and antibody candidates for solid tumors. In the Phase I trial presented at ASCO, a group of patients with...
China to open borders for patients travelling for medical treatment
China to open its borders for the first time since COVID pandemic outbreak. Borders will open for all types of visa. Check how to obtain medical visa for...
March month is colorectal cancer awareness month
March month if observed as colorectal cancer awareness month. Colorectal cancer is second most deadly cancer on this planet and early diagnosis is required for...
Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy
Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd have entered into a collaborative development programme to develop CAR T Cell therapy for...
New drug for primary bone cancer in children
As per the report published in the Journal of Bone Oncology, researchers from the University of East Anglia’s Norwich Medical School demonstrated, that the...
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today...
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing...
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and...
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, CHINA, February 28, 2023 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing,...
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing,...
JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients
SHANGHAI, CHINA, November 9, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing,...
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T-cell-based Immunotherapies
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company...
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing,...
How China is leading the development of CAR T-Cell therapy?
The number of CAR-T therapy trials in China surpassed those in the United States by 2018 as a result of this thriving ecosystem. As of June 2022, Chinese...
Cargo, a cancer drug startup, raises $200 million to combat CAR-T relapse
March 2023: Several types of lymphoma, as well as certain leukaemias and multiple myeloma, can now be effectively treated with CAR-T therapy. Recent studies...
New CAR T-Cell therapy drug in lupus renaissance
Feb 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus,...
Perspectives on cancer experiences with oncologist Dr. Willie Goffney
Feb 2023: Check out this tweet from the American Cancer Society that shares a conversation with Dr. Willie Goffney about her perspective on cancer. A tweet...
Enhertu has been approved in China for patients with HER2-positive metastatic breast cancer
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with...
Actor Hamsa Nandini Provides an Update One Year After Breast Cancer Treatment
Feb 2023: Hamsa Nandini, who was diagnosed with Grade III Invasive Carcinoma (Breast Cancer) in 2021, has updated her Instagram followers on her health status....
Global cost of cancer projected to exceed $25 Trillion by 2050
Feb 2023: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25,2 trillion in international dollars (INT)...
Can advanced-stage cancer be cured? Check the latest developments
Check out how the overall landscape of cancer treatment has changed in the last few years. Even advanced-stage cancers can be effectively treated with the...
Kite completes acquisition of Tmunity
Press Release Feb 2023: – Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire...
High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL)...
CAR T-cell treatment provides significant remission rates in clinical trials
Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple...
Novel treatment target for lymphoma patients who relapse after CAR-T therapy
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell...
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics...
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics’ investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track...
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or...
Sacituzumab govitecan-hziy is approved by FDA for HR-positive breast cancer
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor...
Elacestrant is approved by FDA for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced...
Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN...
Pembrolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda,...
Zanubrutinib is approved by FDA for chronic lymphocytic leukemia or small lymphocytic lymphoma
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.